Shanmuga Hospital
A legacy of caring

SHANMUGA HOSPITAL LIMITED
Formerly known as Shanmuga Hospital Private Limited
Reg. Off: 51/24, Saradha College Road, Salem—636 007.
CIN: L85110TZ2020PLC033974 | **GSTIN:** 33ABDCS8326A1ZP
Tele: 0427-2706674 |**E-mail:** secretarial@shanmugahospital.com
Website: www.shanmugahospital.com
ISIN: INE0TD301017 | **Symbol:** SHANMUGA |**Script Code:** 544365

SHL/SE/2026-27/22

11/08/2026

To
The Listing Department
BSE Limited
P. J. Towers, Dalal Street,
Mumbai-40000, Maharashtra
Scrip Code: 544365 | **ISIN:** INE0TD301017

SUB: Outcome of Board Meeting.

Dear Sir/ Madam,

In compliance with 30 and 33 of SEBI (Listing Obligation and Disclosure Requirement) Regulation, 2015 ("SEBI Listing Regulation"), the board of directors of the company at their meeting held today., Tuesday, August, 11, 2026, has inter alia, Consider and approved the following:

a. The Unaudited Financial Results of the Company for the quarter ended June 30, 2026, as recommended by the Audit Committee, together with the Limited Review Report issued by the Statutory Auditors of the Company, in compliance with Regulation 33 of the SEBI (LODR) Regulations, 2015, enclosed as "**Annexure – A**".

b. Entering into the power purchase agreement ("PPA") with LNGS Private Limited for procurement of electricity for the company. Details as required under Regulation 30 of the Listing Regulations read with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is attached herewith as ***Annexure – B***.

c. Approved the Notice convening the 06th Annual General Meeting of the Company to be held on Friday, 18th September, 2026 at 02:30 P.M. through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The Notice of 6th Annual General Meeting and Annual Report for the FY 2025-26 will be sent through electronic mode to those Shareholders whose email address are registered with the Company/Registrar & Share Transfer Agents of the Company and with their respective DP's. Further, the Letter to Shareholders whose e-mail addresses are not registered with the Company or its Registrar & Share Transfer Agent or Depository Participant(s) will also be dispatched in term of Regulation 36(1)(b) of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015.

d. Formulation of Employee Stock Option Plan, viz., "Shanmuga Hospital Limited Employee Stock Option Plan 2026" ("SHL ESOP-2026"), in terms of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. Details as required under Regulation 30 of the Listing Regulations read with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is attached herewith as ***Annexure – C***.

e. Appointment of M/s Finshore Management Service Ltd. as the Merchant Banker for Employee Stock Option Plan.

f. Approval for increase in the Authorized Share Capital and subsequent amendment in the share capital clause of Memorandum of Association of the Company. The Board of Directors has approved the increase in authorised share capital of the Company from Rs. 14,00,00,000/- divided into 1,40,00,000 equity shares of Rs. 10/- each to Rs. 25,00,00,000/- divided into 2,50,00,000 equity shares of Rs. 10/- each subject to approval of Shareholders of the Company at the ensuing Annual General Meeting.

The Clause V of the Memorandum of Association is substituted as herein below "The Authorised share capital of the Company is Rs. 25,00,00,000/- (Rupees Twenty-Five Crores) divided into 2,50,00,000 (Two Crore Fifty Lakhs) equity shares of Rs.10/- (Rupees One) each."

g. Alteration of Main Object Clause of the Memorandum of Association

The Board of Directors considered and approved the proposal for alteration of the Main Object Clause of the Memorandum of Association (MOA) of the Company by insertion of two new Main Object Clauses, with a view to enabling the Company to undertake the proposed business activities in the future, subject to the approval of the Members of the Company at the ensuing Annual General Meeting (AGM) and such other approvals as may be required.

The proposed new Main Object Clauses are intended to provide the Company with the flexibility to diversify and expand its business activities in line with its future plans and business opportunities.

Accordingly, the Board approved the proposal for insertion of the following two new Main Object Clauses in the MOA of the Company:

Addition of Clause 5 and 6 to the Main Object Clause of the Memorandum of Association of the Company

"5. *To carry on the business of providing administrative, operational, management, technical, academic, training, consultancy and other allied support services to medical colleges, nursing colleges, paramedical institutions, teaching hospitals, healthcare institutions and other medical educational establishments.*

6. To carry on the business of designing, developing, creating, owning, licensing, marketing, selling, distributing, implementing, maintaining, upgrading and otherwise dealing in computer software, software products, mobile applications, web applications

and other digital applications and solutions, whether developed by the Company or otherwise acquired, in India or abroad."

The necessary resolution for alteration of the Main Object Clause of the MOA by insertion of the aforesaid new Main Object Clauses shall be placed before the Members for their approval at the ensuing AGM.

h. Alteration of Articles of Association

The Board considered and approved the proposal for alteration of certain provisions of the existing Articles of Association ("AOA") of the Company, primarily relating to (i) Definitions/Interpretation, (ii) Share Capital and (iii) Variation of Rights of Shareholders, with a view to updating and aligning the relevant provisions with the present requirements and future growth plans of the Company.

The Board approved the proposal for alteration and adoption of the amended and restated AOA, subject to the approval of the Members of the Company by way of a Special Resolution at the ensuing Annual General Meeting ("AGM").

The detailed proposed amendments, together with the rationale and other requisite disclosures, shall be provided in the Notice convening the ensuing AGM.

i. **Record Date** to Determination of members eligible to receive notice and vote at the AGM is 11.09.2026.

j. **Book Closure** the Register of Members and Share Transfer Books of the Company will remain closed from 12.09.2026 to 18.09.2026.

k. The board appointed CS Santhanakrishna Anuradha, Practicing Company Secretary, Salem has a Secrutinizer for the 6th Annual General Meeting.

SHANMUGA HOSPITAL LIMITED
Formerly known as Shanmuga Hospital Private Limited
Reg. Off: 51/24, Saradha College Road, Salem—636 007.
CIN: L85110TZ2020PLC033974 | **GSTIN:** 33ABDCS8326A1ZP
Tele: 0427-2706674 |**E-mail:** secretarial@shanmugahospital.com
Website: www.shanmugahospital.com
ISIN: INE0TD301017 | **Symbol:** SHANMUGA |**Script Code:** 544365

The Board meeting commenced at 03:00 PM and ends at 05:50 PM.

This is for your information and records.

Thanking you,

For Shanmuga Hospital Limited
ANJANA MARAGATHAM
Digitally signed by ANJANA MARAGATHAM
Date: 2026.08.11 18:09:40 +05'30'

Kannan Anjana Maragatham
Company Secretary & Compliance Officer
M. No. A70080

P P N AND COMPANY
CHARTERED ACCOUNTANTS
No.2, IV Cross Street, Sterling Road, Nungambakkam, Chennai - 600034.
(Near to Loyola College) Ph : 044 - 2828 0033, Cell : 98847 46227
E-mail : info@ppnaco.com | Web : www.ppnaco.com

Independent Auditor's Limited Review Report on unaudited standalone financial results of Shanmuga Hospital Limited for the quarter ended June 30, 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To,
The Board of Directors,
Shanmuga Hospital Limited.

1. We have reviewed the accompanying statement of unaudited standalone financial results of Shanmuga Hospital Limited ("the Company"), for the quarter ended June 30, 2026 ("the statement"). The Statement has been prepared by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended ("the Listing Regulation").

2. The Company's management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Accounting Standards (AS 25) "Interim Financial Reporting", prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the financial statements based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free from material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters and applying analytical and other review procedures to financial data. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Thus, we have not performed an audit and accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No.CIR/CFD/CMD1/44/2019 dated March 29, 2019, issued by the Securities and

P P N AND COMPANY CHENNAI CHARTERED ACCOUNTANTS

Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of the unaudited standalone financial results read with notes thereon, prepared in accordance with applicable accounting standards specified under section 133 of the Companies Act, 2013 as amended, read with rules issued thereunder and other recognised accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P P N And Company
Chartered Accountants
Firm's Registration No: 013623S
Peer review Certificate No.020690

R. RAJARAM
Partner
Membership No.238452
UDIN: 26238452BMEAFR7998

Date : 11-08-2026
Place: Chennai

SHANMUGA HOSPITAL LIMITED
(formerly known as Shanmuga Hospital Private Limited)
CIN: L85110TZ2020PLC033974
Registered Office: 51/24, Saradha College Road, Salem, Tamil Nadu, India-636007

(All Amounts are in Rs.Lakhs except for No. of Shares & EPS)

Statement of Standalone Unaudited Financial Results for the Quarter ended 30th June, 2026

	Particulars	Quarter Ended 30th June, 2026	Quarter Ended 31st March, 2026	Quarter Ended 30th June, 2025	Year Ended 31st March, 2026
		Unaudited	Audited	Unaudited	Audited
I	Revenue From Operations	1,186.71	1,085.34	1,148.21	4,743.61
II	Other Income	4.27	14.58	9.73	62.71
III	**Total Income (I+II)**	**1,190.98**	**1,099.92**	**1,157.94**	**4,806.32**
IV	**Expenses**				
	Cost of Consumption	268.72	281.94	381.41	1,474.72
	Employee Benefits Expenses	221.68	192.55	140.63	757.98
	Finance Costs	8.14	9.17	8.75	42.15
	Depreciation & Amortisation Expenses	74.83	50.06	81.42	281.65
	Other Expenses	486.06	426.84	415.82	1,682.79
	Total Expenses (IV)	**1,059.43**	**960.56**	**1,028.02**	**4,239.30**
V	**Profit Before Exceptional and Extraordinary Items and Tax (III-IV)**	**131.56**	**139.35**	**129.92**	**567.02**
VI	Exceptional Items				
VII	**Profit Before Extraordinary Items and Tax (V-VI)**	**131.56**	**139.35**	**129.92**	**567.02**
VIII	Extraordinary Items				
IX	**Profit Before Tax (VII-VIII)**	**131.56**	**139.35**	**129.92**	**567.02**
X	**Tax Expense:**				
	(1) Current Tax	22.90	17.28	18.22	82.38
	(2) Deferred Tax	10.01	16.98	16.72	63.58
XI	**Profit/(Loss) For The Period (IX-X)**	**98.65**	**105.09**	**94.98**	**421.06**
	Earnings per Equity Share: (In Rs.) (Not annualised)				
	(1) Basic	0.72	0.77	0.70	3.09
	(2) Diluted	0.72	0.77	0.70	3.09
	Paid up Equity Share Capital				
	Total no. of Shares (Weighted Average)	13,613,000	13,613,000	13,613,000	13,613,000
	Face Value Per Share	10	10	10	10

Notes on Standalone Financial Results:

1 The above results which are published in accordance with Regulations 33 of SEBI (Listing Obligation & Disclosure Requirements), 2015 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on August 11th, 2026. The Financial results have been prepared in accordance with the Accounting Standards ("AS") as prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of Companies (Account) Rules 2014 by the Ministry of Corporate Affairs and amendments thereof.

2 The Company is voluntarily disclosing unaudited quarterly financial results for the quarter ended 30th June, 2026 to promote enhanced investor transparency and timely communication. Such quarterly disclosures are not mandatory under the SME Listing framework prescribed by SEBI.

3 As per Ministry of Corporate Affairs Notification dated February 16, 2015. Companies whose securities are listed on SME Exchange as referred to in Chapter XB of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009 are exempted from the compulsory requirement of adoption of Ind AS.

4 As the Company collectively operates only in one business Segment, hence, it is reporting its results in single Segment. Therefore, segment disclosure is not applicable.

5 The Company does not have any subsidiary/ associate/ joint venture entity(ies) for the respective period.

6 EPS is not annualized for the Quarterly results. The EPS has been computed based on weighted average number of equity shares outstanding for the respective periods

7 The figures for the corresponding previous periods / year have been regrouped / reclassified wherever necessary.

8 There were no exceptional and extra-ordinary items for the reporting period.

SHANMUGA HOSPITAL LIMITED SALEM-7

For and on behalf of the Board of Directors of
SHANMUGA HOSPITAL LIMITED
(formerly known as Shanmuga Hospital Private Limited)

Dr. P Prabu Sankar
Executive Director & Chief Executive Officer
DIN: 08772888

Place: Salem
Date: 11-08-2026

Shanmuga Hospital
A legacy of caring

SHANMUGA HOSPITAL LIMITED
Formerly known as Shanmuga Hospital Private Limited
Reg. Off: 51/24, Saradha College Road, Salem—636 007.
CIN: L85110TZ2020PLC033974 | **GSTIN:** 33ABDCS8326A1ZP
Tele: 0427-2706674 |**E-mail:** secretarial@shanmugahospital.com
Website: www.shanmugahospital.com
ISIN: INE0TD301017 | **Symbol:** SHANMUGA |**Script Code:** 544365

Annexure – B

S. No.	Particulars of Disclosure	Disclosure
1.	**Name(s) of parties with whom the agreement is entered;**	Shanmuga Hospital Limited and LNGS Private Limited
2.	**Purpose of entering into the agreement;**	To procure electricity from LNGS Private Limited for meeting the power requirements of Shanmuga Hospital Limited.
3.	**Size of agreement;**	The Company proposes to procure electricity at a tariff of ₹6.10 per unit. The overall value of procurement shall depend upon actual electricity consumption during the tenure of the Power Purchase Agreement ("PPA")
4.	**Shareholding, if any, in the entity with whom the agreement is executed;**	The Company proposes to invest 1% of the paid-up share capital of LNGS Private Limited as a condition of the proposed PPA arrangement.
5.	**Significant terms of the agreement (in brief)**	(i) Procurement of electricity at a tariff of ₹6.50 per unit. (ii) Investment by the Company in 1% of the equity share capital of LNGS Private Limited as a condition precedent to the proposed Power Purchase Agreement (PPA) arrangement.
6.	**Whether, the said parties are related to promoter/promoter group/ group companies in any manner.**	Not Applicable. LNGS Private Limited is not related to the promoter/promoter group/group companies of Shanmuga Hospital Limited.
7.	**Whether the transaction would fall within related party transactions**	Not Applicable
8.	**In case of issuance of shares to the parties, details of issue price, class of shares issued**	Not Applicable
9.	**In case of loan agreements, details of lender/borrower, nature of the loan, total amount of loan granted/taken, total amount outstanding, date of**	Not Applicable

	execution of the loan agreement/sanction letter, details of the security provided to the lenders / by the borrowers for such loan or in case outstanding loans lent to a party or borrowed from a party become material on a cumulative basis	
10.	**Any other disclosures related to such agreements,**	The Board has authorized Dr. Prabu Sankar Panneerselvam, Director & Chief Executive Officer, to negotiate, finalize and execute the PPA,
11.	**In case of termination or amendment of agreement**	Not Applicable

Shanmuga Hospital
A legacy of caring

SHANMUGA HOSPITAL LIMITED
Formerly known as Shanmuga Hospital Private Limited
Reg. Off: 51/24, Saradha College Road, Salem—636 007.
CIN: L85110TZ2020PLC033974 | **GSTIN:** 33ABDCS8326A1ZP
Tele: 0427-2706674 |**E-mail:** secretarial@shanmugahospital.com
Website: www.shanmugahospital.com
ISIN: INE0TD301017 | **Symbol:** SHANMUGA |**Script Code:** 544365

Annexure – C

S. No.	Particulars of Disclosure	Disclosure
1.	**Brief details of options granted**	On the recommendations of the Nomination and Remuneration Committee (NRC), the Board of Directors of the Company have approved the ***"Shanmuga Hospital Ltd. Employee Stock Option Plan 2026"*** (hereinafter referred to as the "Plan") with the authority to grant not exceeding 3,50,000 (Three Lakh Fifty Thousand) Employee Stock Options to such Eligible Employees of the Company as may be determined by the NRC (also designated as Compensation Committee), in one or more tranches, from time to time, which in aggregate shall be exercisable into not more than 3,50,000 (Three Lakh Fifty Thousand) equity shares of face value of Rs. 10/- (Rupees Ten Only) each fully paid-up, subject to approval of the shareholders at the AGM of the Company and such other regulatory/statutory approvals as may be necessary.
2.	**Whether the scheme is in terms of SEBI (SBEB) Regulations, 2021 (if applicable);**	Yes.
3.	**Total number of shares covered by these options;**	3,50,000 (Three Lakh Fifty Thousand) equity shares of face value of Rs. 10/- (Rupees Ten Only) each fully paid-up corresponding to 2.58% of the total paid-up equity share capital of the Company.
4.	**Pricing formula**	The Exercise Price of any Option granted under the Plan shall be the price for Exercise of Options as determined by the NRC which shall not be less than the face value of the equity shares and not more than the closing market price as on the previous day of the date of Grant communicated to the Participating Employee vide the Option Grant Agreement or such other mode as the NRC may deem fit. Once granted, the Exercise Price of the Options may be varied by the NRC to account for any rights issues, mergers, stock splits, bonus issue or share consolidations etc.

5.	**Options vested**	NIL
6.	**Time within which option may be exercised**	Exercise Period shall be a period of 1 (one) year from the date of Vesting, within which the Vested Options may be Exercised by the Option Grantee.
7.	**Options Exercised**	NIL
8.	**Money realized by exercise of options**	NIL
9.	**The total number of shares arising as a result of exercise of option**	NIL
10.	**Options lapsed**	NIL
11.	**Variation of terms of options**	NRC may make modifications, changes, variations, alterations or revisions in the Plan as it may deem fit, from time to time in its sole and absolute discretion, not unfavourable or prejudicial to the allottees under the Plan except due to change in laws/regulations, and in conformity with the provisions of the Companies Act, 2013, the Memorandum and Articles of Association of the Company, SEBI Regulations and any other applicable laws.
12.	**Brief details of significant terms**	Options granted under this plan shall vest not earlier than minimum period of 1 (One) year and not later than the maximum Period of 3 (Three) years from the date of Grant of respective options.
13.	**Subsequent changes or cancellation or exercise of such options**	NA
14.	**Diluted earnings per share pursuant to issue of equity shares on exercise of options.**	NA

For Shanmuga Hospital Limited
ANJANA MARAGATHAM
Digitally signed by ANJANA MARAGATHAM
Date: 2026.08.11 18:10:17 +05'30'
Kannan Anjana Maragatham
Company Secretary & Compliance Officer
M. No. A70080